Skip to main content
Fresenius SE & Co. KGaA logo

Fresenius SE & Co. KGaA — Investor Relations & Filings

Ticker · FRE ISIN · DE0005785604 LEI · XDFJ0CYCOO1FXRFTQS51 F Human health and social work activities
Open in API
Filings indexed 1,398 across all filing types
Latest filing 2019-04-30 Declaration of Voting R…
Country DE Germany
Listing F FRE

About Fresenius SE & Co. KGaA

https://www.fresenius.com/

Fresenius SE & Co. KGaA is a global healthcare company that provides system-critical products and services for leading therapies for the care of critically and chronically ill patients. The company's portfolio encompasses a wide range of products and services for dialysis, hospitals, and outpatient medical care. Key offerings include intravenously administered generic drugs, biopharmaceuticals, biosimilars, clinical nutrition, and infusion therapies. Additionally, the company operates a large network of private hospitals and outpatient centers. Through its strategic investment in Fresenius Medical Care, it is a leading global provider of products and services for individuals with renal diseases.

Recent filings

Filing Released Lang Actions
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Total Voting Rights Announcement' and explicitly mentions the 'Publication of total number of voting rights' as of April 30, 2019. It details a 'Type of capital measure' related to a 'Conditional capital increase' and states the 'New total number of voting rights'. This type of announcement, which reports changes in the total number of shares/voting rights, is most closely aligned with capital structure changes or specific regulatory disclosures regarding share counts. Given the options, 'Share Issue/Capital Change' (SHA) is the most appropriate fit as it deals directly with the total number of shares/voting rights resulting from a capital measure. It is not a general earnings release (ER), a full annual report (10-K), or a director's dealing (DIRS).
2019-04-30 English
Bankhaus Lampe – Deutschlandkonferenz
Investor Presentation Classification · 99% confidence The document is a presentation titled 'Bankhaus Lampe Deutschlandkonferenz' dated '04 April 2019'. It contains detailed financial figures for the Fiscal Year 2018 (FY/18), including sales, EBIT, and segment performance across Fresenius Medical Care, Fresenius Kabi, Helios Germany, Helios Spain, and Fresenius Vamed. It also discusses future targets (FY/19, 2020-2023) and capital deployment. This structure—a detailed review of the past year's performance presented to investors/analysts—is characteristic of an Investor Presentation (IP). It is not a formal regulatory filing like a 10-K, nor is it a brief earnings release (ER).
2019-04-04 English
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly announces the 'Total Voting Rights' as of March 31, 2019, referencing Article 41 of the WpHG (German Securities Trading Act). It details a 'Type of capital measure' which is a 'Conditional capital increase' and states the 'New total number of voting rights'. This type of announcement, concerning the total number of shares/voting rights, is a specific regulatory disclosure. While it is a regulatory announcement, it is not a general RNS, nor is it a dividend (DIV), director dealing (DIRS), or major shareholding (MRQ). It is most closely related to changes in capital structure or shareholder rights reporting. Given the options, this specific disclosure about the total number of voting rights following a capital measure fits best under 'Share Issue/Capital Change' (SHA) as it directly relates to the denominator of ownership percentages, or potentially 'Regulatory Filings' (RNS) if SHA is too specific for this exact format. However, since it details a capital measure ('Conditional capital increase') and the resulting total shares, SHA is the most precise fit among the provided codes for capital structure changes affecting the total share count. If SHA is reserved strictly for primary issuance announcements, RNS would be the fallback. Given the context of capital structure change reporting, SHA is selected.
2019-03-31 English
Roadshow Melbourne
Investor Presentation Classification · 98% confidence The document is titled "Roadshow Hong Kong" and dated March 28, 2019. It contains extensive slides detailing the company's global healthcare portfolio (Fresenius Medical Care, Kabi, Helios, Vamed), financial performance for FY/18 (including P&L statements, segment growth), strategic outlook, capital deployment plans, and specific growth targets for 2019-2023. This format—a detailed presentation given to investors, covering past performance and future strategy—is characteristic of an Investor Presentation (IP). It is not a formal regulatory filing like a 10-K, nor is it a brief earnings release (ER). The length and depth confirm it is a presentation document.
2019-03-28 English
Roadshow Taipeh
Investor Presentation Classification · 99% confidence The document is titled 'Roadshow Taipei' and contains extensive slides detailing financial performance ('~€33.5 bn in Sales as of Dec. 31, 2018'), segment performance (Fresenius Medical Care, Kabi, Helios, Vamed), investment plans, and forward-looking statements. It includes detailed financial tables for Q4/18 and FY/18, such as the 'Q4/18 & FY/18 Profit and Loss Statement'. This structure is characteristic of an Investor Presentation (IP) used during roadshows or investor days to present strategy and results, rather than a formal regulatory filing like a 10-K or a brief Earnings Release (ER). The length (over 6,500 characters) confirms it is a detailed presentation, not just an announcement of a report (RPA/RNS).
2019-03-27 English
DGAP-DD: Fresenius SE & Co. KGaA english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'DGAP-DD: Fresenius SE & Co. KGaA english' and contains the header 'Directors’ Dealings'. Section 1 identifies the person as Stephan Sturm, a 'Member of the managing body'. Section 4 details the 'Nature of the transaction' as 'Acquisition' of shares, including price and volume. This content directly corresponds to the definition of Director's Dealing reports, which are classified under the code DIRS.
2019-03-26 English

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.